coyatherapeutics.com (COYA): יחס חוב להיוון בספרים

Coya Therapeutics, Inc. (COYA) is scaling the production of cell therapies through Texas-based laboratories and a network of external CDMO partners. The debt-to-equity ratio confirms the financial strategy, with the indicator standing at 0.00. The company is developing Treg therapy to combat Alzheimer's and ALS in collaboration with Dr. Reddy’s. High clinical trial participant loyalty and strict FDA oversight ensure a steady flow of investment into neurobiotech.

For the long-term investor, the financial stability of Coya Therapeutics, Inc. (COYA) serves as a key safety factor. This metric measures the proportion of debt capital relative to the company's equity, determining the business's degree of dependence on creditors. By analyzing changes in the ratio of total debt to book capitalization, one can assess the risk of bankruptcy during macroeconomic shocks. A low debt load confirms stability secured by long-term grants and partnerships. Such a capital structure guarantees that the development of therapies remains independent of market cyclicality.